Xarelto Claims Continue To Be Filed

http://www.digitaljournal.com/pr/3084263

Xarelto is in a new class of medication (NOAC) novel oral anticoagulants that competes with the old standard Coumadin (Warfarin)… Only Pradaxa now has a “reversal agent” that can take up to 12 hrs to reverse the blood thinning – slower clotting – effect of Pradaxa and some 21% it will not reverse this issue… putting many people at imminent risk of death.  The “old standard” uses, very successfully, Vitamin K  to reverse the slower blood clotting process.

From the financial perspective Xarelto cost around $400 for a 3o days supply… vs $20 -$30 for a month’s supply of Warfarin and the Vitamin K antidote is likewise very affordable.  With today’s technology, pts can do the blood testing of how effective Warfarin is working now with a small meter in their own home for about $25/test… once a pt is stable on Warfarin… testing can normally be done … once a month…  Besides the safety issue… the use of Warfarin can be much more affordable for the pt.

Since it was first approved in 2011, Xarelto has been making headlines but most of them are for claims filed against the manufacturer of the drug. Approved in the United States for use in 2011, Xarelto is a blood thinner manufactured by Bayer and marketed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. The drug earned more than $2 billion for its manufacturers in 2015 alone and has netted over $500 million so far in 2016. Those affected by the drug are claiming that the manufacturer and distributor of the drug are putting their profits above the safety of their customers.

Drug-Lawsuits.org provides information to consumers about the multitude of lawsuits that have been filed against the makers and distributors of the drug. A spokesperson for the site says, “There are thousands of lawsuits regarding Xarelto, more than 4,500 that will be heard before a Louisiana judge, and a number of others filed in other states throughout the nation.”

Most recently, a woman from Florida filed allegations against Janssen Pharmaceuticals claiming that her husband suffered from atrial fibrillation, an irregular heartbeat, after being administered the medication. The patient began bleeding between his brain and its outermost covering, a condition known as a subdural hemorrhage. Physicians were unable to control the bleeding and the patient died as a result of his injuries, which his wife claim were the direct result of taking Xarelto.

“She’s not the only person who has lost someone,” says the spokesperson for www.xarelto-lawsuits.org. “Everyone who has a part in these lawsuits has watched a loved one suffer or even die.”

Doctors are unable to find a method of controlling the bleeding that is brought on by the use of the blood thinner. When Xarelto was first introduced, it was considered an alternative to other blood thinning medications because no special blood monitoring was required. Today however, many patients have learned that monitoring not only seems necessary, but it can be life-saving and many of those affected by use of the drug claim that the pharmaceutical company dropped the ball with regards to warning the public about the potentially fatal side effects.

Plaintiffs like the widow from Florida are continuing to file lawsuits against the maker and distributor of the drug, and trials are scheduled to begin early in 2017 for those suits already filed.

###

Contact Drug-Lawsuits.org:

info@drug-lawsuits.org

Filed under: General Problems